Almirall, S.A.
General ticker "LBTSF" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $2.4B (TTM average)
Almirall, S.A. follows the US Stock Market performance with the rate: 45.7%.
Estimated limits based on current volatility of 0.0%: low 15.35$, high 15.35$
Factors to consider:
- Company pays dividends (irregularly): last record date 2025-05-16, amount 0.21$ (Y1.37%)
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [14.10$, 21.91$]
- 2026-12-31 to 2027-12-31 estimated range: [13.75$, 21.68$]
Financial Metrics affecting the LBTSF estimates:
- Positive: with PPE of 49.2 at the end of fiscal year the price was low
- Positive: -4.75 < Operating profit margin, % of 6.11
- Positive: -14.22 < Investing cash flow per share per price, % of -4.70
- Positive: 42.68 < Shareholder equity ratio, % of 63.63 <= 64.29
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 1.94
- Positive: Inventory ratio change, % of -0.98 <= -0.75
- Negative: negative Industry operating cash flow (median)
- Positive: 0.01 < Operating cash flow per share per price, % of 5.98
Short-term LBTSF quotes
Long-term LBTSF plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | €894.52MM | €985.72MM | €1,107.67MM |
| Operating Expenses | €899.78MM | €949.63MM | €1,039.98MM |
| Operating Income | €-5.26MM | €36.09MM | €67.69MM |
| Non-Operating Income | €-11.93MM | €-9.59MM | €6.73MM |
| Interest Expense | €7.21MM | €17.00MM | €17.85MM |
| R&D Expense | €66.91MM | €79.00MM | €138.05MM |
| Income(Loss) | €-17.19MM | €26.50MM | €74.42MM |
| Taxes | €21.28MM | €0.00MM | €28.28MM |
| Profit(Loss)* | €-38.47MM | €10.15MM | €46.18MM |
| Stockholders Equity | €1,463.40MM | €1,488.38MM | €1,486.58MM |
| Inventory | €167.37MM | €171.69MM | €178.07MM |
| Assets | €2,374.99MM | €2,396.66MM | €2,336.26MM |
| Operating Cash Flow | €93.48MM | €160.77MM | €169.14MM |
| Capital expenditure | €159.30MM | €161.43MM | €34.90MM |
| Investing Cash Flow | €-122.56MM | €-140.04MM | €-132.89MM |
| Financing Cash Flow | €168.21MM | €-31.58MM | €-75.56MM |
| Earnings Per Share** | €-0.20 | €0.04 | €0.22 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.